Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for KRYS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 272.34M
March 31, 2026 250.28M
December 31, 2025 200.86M
September 30, 2025 176.20M
June 30, 2025 195.40M
March 31, 2025 138.50M
December 31, 2024 123.42M
September 30, 2024 63.34M
June 30, 2024 -16.74M
March 31, 2024 -46.76M
December 31, 2023 -88.80M
September 30, 2023 -103.90M
June 30, 2023 -102.36M
March 31, 2023 -111.23M
December 31, 2022 -100.57M
September 30, 2022 -99.14M
June 30, 2022 -86.71M
March 31, 2022 -53.78M
December 31, 2021 -47.94M
September 30, 2021 -35.06M
Date Value
June 30, 2021 -34.57M
March 31, 2021 -29.51M
December 31, 2020 -26.08M
September 30, 2020 -25.10M
June 30, 2020 -22.58M
March 31, 2020 -21.72M
December 31, 2019 -18.71M
September 30, 2019 -15.18M
June 30, 2019 -12.88M
March 31, 2019 -10.29M
December 31, 2018 -9.445M
September 30, 2018 -8.054M
June 30, 2018 -7.212M
March 31, 2018 -6.002M
December 31, 2017 -3.89M
September 30, 2017 -2.624M
June 30, 2017 -1.837M
March 31, 2017 -1.568M
December 31, 2016 -1.311M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Marker Therapeutics, Inc. -9.756M
TG Therapeutics, Inc. 17.88M
Cytokinetics, Inc. -555.45M
ADMA Biologics, Inc. 136.72M
Alnylam Pharmaceuticals, Inc. 885.89M